Oluwaseun Falade-Nwulia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8292232/publications.pdf

Version: 2024-02-01

56 papers 2,065 citations

430754 18 h-index 243529 44 g-index

57 all docs

57 docs citations

57 times ranked

3473 citing authors

#	Article	IF	Citations
1	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection. Annals of Internal Medicine, 2017, 166, 637.	2.0	540
2	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 1477-1492.	2.9	509
3	Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses, 2012, 55, 290-297.	1.8	129
4	Understanding and addressing hepatitis C reinfection in the oral directâ€acting antiviral era. Journal of Viral Hepatitis, 2018, 25, 220-227.	1.0	75
5	Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nature Communications, 2012, 3, 716.	5. 8	57
6	Public health clinicâ€based hepatitis C testing and linkage to care in baltimore. Journal of Viral Hepatitis, 2016, 23, 366-374.	1.0	51
7	Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. Journal of Substance Abuse Treatment, 2019, 100, 45-51.	1.5	49
8	Comparative Risk of Liver-Related Mortality From Chronic Hepatitis B Versus Chronic Hepatitis C Virus Infection. Clinical Infectious Diseases, 2012, 55, 507-513.	2.9	42
9	High hepatitis C cure rates among black and nonblack human immunodeficiency virus–infected adults in an urban center. Hepatology, 2017, 66, 1402-1412.	3.6	39
10	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD. PLoS ONE, 2019, 14, e0224686.	1.1	38
11	Staying hepatitis C negative: A systematic review and metaâ€analysis of cure and reinfection in people who inject drugs. Liver International, 2019, 39, 2244-2260.	1.9	36
12	Racial Disparities in Overdose Prevention among People Who Inject Drugs. Journal of Urban Health, 2020, 97, 823-830.	1.8	35
13	A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study. Open Forum Infectious Diseases, 2019, 6, ofz166.	0.4	34
14	A longitudinal study of vaccine hesitancy attitudes and social influence as predictors of COVID-19 vaccine uptake in the US. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	1.4	33
15	Genomic diversity of SARS-CoV-2 during early introduction into the Baltimore–Washington metropolitan area. JCl Insight, 2021, 6, .	2.3	31
16	Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods. Annals of Internal Medicine, 2015, 163, 673-680.	2.0	28
17	Behavioral and Attitudinal Correlates of Trusted Sources of COVID-19 Vaccine Information in the US. Behavioral Sciences (Basel, Switzerland), 2021, 11, 56.	1.0	27
18	Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. Open Forum Infectious Diseases, 2017, 4, ofx024.	0.4	22

#	Article	IF	CITATIONS
19	Hepatitis C treatment uptake among people who inject drugs in the oral directâ€acting antiviral era. Liver International, 2020, 40, 2407-2416.	1.9	19
20	Individual and network factors associated with HCV treatment uptake among people who inject drugs. International Journal of Drug Policy, 2020, 78, 102714.	1.6	19
21	Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era. , 2016, 06, .		18
22	Networkâ€based recruitment of people who inject drugs for hepatitis C testing and linkage to care. Journal of Viral Hepatitis, 2020, 27, 663-670.	1.0	18
23	Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. Mycoses, 2011, 54, e877-e879.	1.8	17
24	The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection. Journal of Hepatology, 2017, 66, 267-269.	1.8	17
25	Liver disease, HIV and aging. Sexual Health, 2011, 8, 512.	0.4	16
26	Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum. Open Forum Infectious Diseases, 2019, 6, ofz426.	0.4	14
27	HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014–2015. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 559-567.	0.9	12
28	Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs. Addictive Behaviors, 2019, 96, 56-61.	1.7	11
29	Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore. Infection, Genetics and Evolution, 2020, 77, 104078.	1.0	11
30	Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland. Journal of Viral Hepatitis, 2020, 27, 1388-1395.	1.0	9
31	Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore. BMC Infectious Diseases, 2020, 20, 815.	1.3	9
32	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. Journal of Infectious Diseases, 2020, 222, S745-S757.	1.9	9
33	The Influence of PrEP-Related Stigma and Social Support on PrEP-Use Disclosure among Women Who Inject Drugs and Social Network Members. AIDS and Behavior, 2021, 25, 3922-3932.	1.4	9
34	The Relationship between Neighborhood Disorder, Social Networks, and Indoor Cigarette Smoking among Impoverished Inner-City Residents. Journal of Urban Health, 2017, 94, 534-541.	1.8	8
35	Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. International Journal of Drug Policy, 2021, 88, 103019.	1.6	7
36	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. International Journal of Drug Policy, 2021, 96, 103469.	1.6	7

#	Article	IF	Citations
37	Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening. , 2016, 6, .		6
38	Senior Center-Based Hepatitis C Screening in Baltimore. Open Forum Infectious Diseases, 2016, 3, ofv217.	0.4	6
39	Unreported alcohol use was common but did not impact hepatitis C cure in HIVâ€infected persons who use drugs. Journal of Viral Hepatitis, 2020, 27, 476-483.	1.0	5
40	Public Health Clinic–Based Hepatitis C Treatment. American Journal of Preventive Medicine, 2020, 59, 420-427.	1.6	5
41	An Education and Field Experience Program to Increase Detection of Human Immunodeficiency Virus and Hepatitis C Virus. Progress in Community Health Partnerships: Research, Education, and Action, 2018, 12, 101-109.	0.2	4
42	Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs. Journal of Infectious Diseases, 2022, 225, 903-911.	1.9	4
43	HCV communication within ego-centric networks of men and women who inject drugs. Drug and Alcohol Dependence, 2021, 229, 109157.	1.6	4
44	Characterizing latent classes of social support among persons who inject drugs. Drug and Alcohol Dependence, 2020, 207, 107816.	1.6	3
45	Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy. Aids, 2021, 35, 991-993.	1.0	3
46	The impact of social network dynamics on engagement in drug use reduction programs among men and women who use drugs. Journal of Substance Abuse Treatment, 2022, 137, 108713.	1.5	2
47	A 36-Year-Old Haitian Man With Coma, Acute Kidney Injury, Lactic Acidosis, and Respiratory Failure. Chest, 2012, 142, 798-801.	0.4	1
48	1291Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to Care. Open Forum Infectious Diseases, 2014, 1, S49-S49.	0.4	1
49	Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs. Drug and Alcohol Dependence, 2022, 230, 109177.	1.6	1
50	A23â€fPopulation level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD. Virus Evolution, 2019, 5, .	2.2	0
51	Hepatitis C Virus Elimination Requires More Than Good Drugs. Clinical Infectious Diseases, 2020, 71, 1269-1270.	2.9	O
52	Impact of co-occurring drug use, hazardous alcohol use and mental health disorders on drug use patterns in people living with HIV and hepatitis C virus infection. Open Forum Infectious Diseases, 2021, 8, ofab520.	0.4	0
53	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0
54	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0

#	Article	IF	CITATIONS
55	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		O
56	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0